
Peer-Led Weight Loss Maintenance Proves Superior
Can a mentor/peer-led strategy surpass professionally led behavioral weight management sessions in helping patients with obesity maintain weight loss? If the findings of a recently published study are any indication, then the promise of keeping weight off after initial weight loss might be closer than ever.
Obesity treatments (eg, bariatric surgery, lifestyle management, and medications like GLP-1s) have been shown in clinical trials and real-life settings to help patients with obesity lose anywhere from 10% to 60% of excess body weight, with added improvements in cardiovascular disease risk factors.
Tricia M. Leahey, PhD
But these gains are commonly fleeting, Tricia M. Leahey, PhD, lead study author, a professor in the Department of Allied Health Sciences, and director of the Institute for Collaboration on Health Intervention and Policy at the University of Connecticut in Storrs, Connecticut, told Medscape Medical News .
'Regardless of how people lose weight, they tend to regain the weight they lost. It starts quickly after initial treatment, and within 1-3 years, most have returned to their pretreatment weight,' she said.
Biology plays a critical role.
'Because of biology — what we call metabolic adaptation to weight loss — the brain is always trying to push people back to their heaviest fat mass, unless they have tools like medicines or surgery,' said Gretchen Aames, PhD, clinical health psychologist and assistant professor of psychology in the Mayo Clinic College of Medicine in Jacksonville, Florida. 'I think that people underestimate the effort that it takes to keep the weight off,' she said.
'There's also psychology and behavior that's associated with weight management,' said Leahy, who added that continuous care strategies (ie, regular professional contact, skills training, and behavioral and social support sessions that are delivered biweekly and gradually tapered over time) can be costly.
From Professional to Peer Support
Leahy and her colleagues have conducted several studies examining the potential role that trained mentors (people who have previously faced and overcome a health situation) and 'peer dyads' (patient pairs initiating health behavior change matched to support one another) might play in helping individuals with obesity maintain initial weight loss.
Their latest effort was a two-phase, proof-of-concept trial in which participants first received a 4-month online obesity treatment lifestyle intervention that was based on the National Diabetes Prevention Program (DPP). (DPP is a lifestyle change program designed to help prevent or delay diabetes in adults with prediabetes.)
In phase 2, participants who achieved ≥ 5% weight loss were randomly assigned to an 18-month patient-provided weight maintenance program (n = 153) or to professionally delivered, 90-minute standard-of-care (SOC) sessions (n = 134) tapered over time. Participants' mean age was 53.6 years, and the majority (83.6%) were women.
Patient-directed programs were delivered by two trained mentors who had previously lost ≥ 7% of body weight and kept it off for ≥ 1 year and who held 90-minute group sessions tapered over time. In the first seven sessions, the content was focused on peer training, empathic listening, and sandwich feedback (initiating feedback with a supportive comment, providing constructive suggestions or support, and ending with a supportive comment.)
Peers were study participants who were randomly paired by gender and age range (18-30 years, 30-40 years); reciprocal support was composed of weekly progress reports and feedback exchanges delivered by text or email.
'We tried to match participants based on similarity and familiarity (ie, how much peers felt similar to or familiar with one another),' explained Leahey. 'We also did relationship development and induction activities (to create emotional closeness) and avoid conflict,' she said.
Participants receiving the mentor/peer intervention were better able to maintain their weight loss compared with SOC participants (mean weight change at month 18: 0.77 [standard deviation, 0.46] kg vs 2.37 [standard deviation, 0.50] kg, respectively) throughout the trial. They also achieved significantly lower cardiovascular measures, namely diastolic blood pressure and resting heart rate, and engaged in significantly more physical activity.
Are Mentor/Peer-Delivered Weight Maintenance Programs Ready for Prime Time?
'A lot of people don't have access to these maintenance interventions due to insurance access or availability of trained providers,' said Kathryn M. Ross, PhD, MPH, senior research scientist at Advocate Aurora Health Research Institute, Milwaukee, and author of the accompanying editorial. 'Looking into newer models that have more implementation potential, such as peer and mentor support, has a lot of potential.'
Kathryn M. Ross, PhD, MPH
'But we don't know from one study if this is something that is ready to take country-wide in clinical practice,' she said. 'It's also unclear which components of the patient-delivered program are critical for successful implementation.'
A key element is training. Leahey emphasized that the researchers continued to refine the training model study by study, eventually landing on factors like age, gender, and empathic listening and feedback strategies that encouraged compassion and cohesiveness.
'I have some patients doing this for me,' said Nida Latif, MD, a family practitioner and obesity specialist running a private practice in Westland, Michigan, and spokesperson for the Obesity Medicine Association, pointing to one in particular.
'She achieved a lot of success (she had bariatric surgery in her 30s and is now in her 60s; she has maintained a BMI of 27-28, from a BMI of 50), she reversed her diabetes and atrial fibrillation and is off all blood pressure medications,' said Latif.
Though Latif said that the patient is a great advocate and has taken some of the burden off her shoulders in terms of time and resource utilization, she emphasized the need for professional oversight.
'Every so often, I have to harness her back. She's come so far that she's forgotten how difficult the change process is. I help her understand that it's a slow process. I identify struggles, the importance of helping patients change just one habit over a period of three to four weeks so they become more consistent,' said Latif.
'Even if it's someone who has had success, they need to adjust to whomever they're trying to help. And touch base with me every so often to discuss challenges.'
Chronic Disease and Chronic Maintenance
An important challenge to weight loss maintenance is the disease itself. Though a chronic illness, obesity is not always accepted as such by physicians or insurers, leaving patients to grapple with weight cycling on their own.
Gretchen Aames, PhD
'If you have to leave your biases at the door,' said Aames. 'There are studies that show that the prevailing thought among primary care physicians and nurses is that weight loss is the patient's responsibility: Eat less, move more. Instead, they should take the time to figure out what their patients know, what they've tried, and things that are sustainable,' she said.
'Maybe they need a little bit of coaching and information and can run with it. Others will need more. We don't know enough yet who is the right person for the peer strategy or the critical components of this type of intervention that will help people.'
For now, physicians might want to help patients build their own support networks to help them keep on track without having to try to set something up within an already time- and resource-crunched practice, said Ross.
Locally run DPP programs (eg, by the Young Men's Christian Association or churches) are a good starting point.
The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases. Leahey, Ross, Aames, and Latif reported no relevant financial relationships.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years – NEW YORK, June 24, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today reported new long-term open-label extension (OLE) data from its phase 2 EMPhASIS trial of lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS). "It is meaningful to see that patients treated with vidofludimus calcium during the OLE period of our phase 2 EMPhASIS trial in RRMS experienced a low rate of confirmed disability worsening (CDW) events, as measured by the Expanded Disability Status Scale (EDSS). This data, representing approximately 952 treatment years, further underlines our belief that vidofludimus calcium holds great potential to effectively manage the disease, help preserve neurological function, allow patients to maintain independence and improve long-term quality of life," stated Andreas Muehler, M.D., M.B.A., Chief Medical Officer of Immunic. The data at week 144 showed that 92.3% of patients remained free of 12-week CDW, and 92.7% free of 24-week CDW. A total of 29 CDW events were confirmed at 12 weeks following the trigger event through week 144. Of these, 44.8% were associated with relapse-associated worsening (RAW), while only 13.8% were associated with progression independent of relapse activity (PIRA). Additionally, the cumulative data available from the EMPhASIS OLE period, thus far, further reinforces the favorable safety and tolerability profile of vidofludimus calcium, showing low discontinuation rates and low rates of treatment-emergent and serious adverse events. Importantly, no new safety signals have emerged during treatment durations up to 5.5 years. "This new data from the OLE period is very encouraging and continues to corroborate the prior strong results we observed in our phase 2 EMPhASIS trial in RRMS," stated Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "The ability to maintain remarkably low rates of disability progression is among the most important unmet needs in relapsing MS despite the availability of multiple anti-inflammatory drugs approved for the treatment of MS relapses. By delaying disease progression, MS patients maintain greater independence, face a lower burden in managing their symptoms and experience more favorable long-term outcomes." "Additionally, previously announced data across our multiple sclerosis (MS) program, including from the EMPhASIS trial as well as our recent top-line data from the phase 2 CALLIPER trial in progressive multiple sclerosis, has further highlighted vidofludimus calcium's potential to slow disease progression in MS and substantiated its neuroprotective capabilities through the activation of the Nurr1 target. As a reminder, despite 30-years of commercially available MS treatments, slowing and preventing disease progression still remains a critical unmet need. Based on the data we have generated, to date, we continue to believe that vidofludimus calcium, with its combined neuroprotective, anti-inflammatory and anti-viral effects as well as its established, highly favorable safety and tolerability profile, could represent a unique new oral therapy targeted to the complex pathophysiology of MS." The phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study, designed to assess the efficacy and safety of vidofludimus calcium in patients with RRMS. The trial randomized 268 RRMS patients and included a 24-week blinded main treatment period testing 10, 30 and 45 mg of vidofludimus calcium and placebo. The trial achieved both primary and key secondary endpoints with high statistical significance and showed a favorable safety and tolerability profile similar to placebo. The trial includes an optional OLE period for up to 9.5 years to evaluate long-term safety and tolerability of vidofludimus calcium. Of the 268 patients that started the double-blind main treatment period, 254 patients continued in the OLE period. Patients were initially given either 30 mg or 45 mg of vidofludimus calcium once-daily, following which all patients received 30 mg of vidofludimus calcium once-daily. At the time of data cutoff on January 14, 2025, 182 patients (71.6% of patients starting OLE) were evaluated up to week 144, which translates into approximately 952 overall treatment years. About Vidofludimus Calcium (IMU-838)Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium is currently being evaluated in phase 3 clinical trials for the treatment of relapsing MS. In a phase 2 clinical trial, it has shown therapeutic activity in relapsing-remitting MS patients, significantly reducing brain lesions and demonstrating encouraging results in reducing confirmed disability worsening. Additionally, vidofludimus calcium has demonstrated clinical benefits in progressive MS patients by showing substantial reductions in confirmed disability worsening and thalamic brain volume in a phase 2 clinical trial. To date, vidofludimus calcium has been exposed to approximately 2,700 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country. About Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, BreuVice President Investor Relations and Communications+49 89 2080 477 US IR ContactRx Communications GroupPaula Schwartz+1 917 633 7790immunic@ US Media ContactKCSA Strategic CommunicationsCaitlin Kasunich+1 212 896 1241ckasunich@ View original content to download multimedia: SOURCE Immunic, Inc.
Yahoo
39 minutes ago
- Yahoo
School Children Jump to Raise $98K for American Heart Association
Families learn life-saving techniques while raising funds for children with special heart needs GRAND RAPIDS, Mich., June 24, 2025 /PRNewswire/ -- Students at 25 National Heritage Academies (NHA)® schools have raised $98,718.59 for the American Heart Association (AHA). The drive, called the Kids Heart Challenge, is a healthy jump-rope event which teaches children about whole body well-being while raising money to help children with special heart needs. Leading the pack of NHA schools was Queen's Grant Community School in North Carolina, which raised $13,675.34, beating their goal of $13K. Queen's Grant Physical Education Teacher Shannon Pearman, in her second year at the school, said the school received overwhelming support from families. "This school does a really good job at community involvement and raising funds for a good cause," she said. "They truly are passionate. We've had a lot of kids who have had heart issues and surgeries, and a lot of families that have been affected." The inclusion of Hands-only CPR training in the drive has also had an incredible impact. Of the 25 NHA schools participating, 432 families have received training in the life-saving technique. "I've really pushed that it's important to know hands-only CPR, whatever the situation might be. In North Carolina, it's a high school requirement for graduation, so in eighth grade we always push to get it done." Pearman said she incentivizes the training with students, so they get their whole families involved. She points out what to do in case of an emergency, and how to start taking care of your heart at an early age. That's where the jump roping comes in. "With kindergarten through second grade students, we need to determine if they can jump rope, then we get into why it's important. With the older kids we can get a little deeper into it and introduce Double-Dutch and tricks." She hosted competitions for students to see how long they can jump without missing. "Last year we had a third-grade student jump for six or seven minutes, and he beat his record this year. Then a fifth grader came in and jumped for 10 minutes straight!" To find the nearest charter school near you, use the NHA school finder . At South Canton Scholars in Michigan, Physical Education Teacher John Howell held a kickoff ceremony for the challenge and students showed their support by wearing red and pink shirts. His school raised $12,891.82 and held a contest for the best jumpers from each grade. "Two boys and two girls were voted as the best jumpers by their classmates," he said. "The finalists competed to determine the best jumpers in each grade. Staff members were the judges, and winners received books and jump ropes as prizes. I also let the scholar with the most donations in each grade K- 5 spend the day as the PE teacher." Classroom teachers play a big role in getting their students involved in jumping rope. They often share childhood memories of jumping rope with friends on the playground. Pearman said it creates a special connection with students. "Having the teachers come in and be a part of it was great. The kids are like 'will you come watch me? I got this trick, will you come do Double-Dutch with me?' So truly, just bringing the whole school together with jump ropes was really cool." NHA Fundraising Totals: Queen's Grant Community School (NC): $ 13,675.34 South Canton Scholars (MI): $ 12,891.82 Summerfield Charter Academy (NC): $10,800.87 Chandler Woods Charter Academy (MI): $ 8, 941.85 Phoenix Academy (NC): $ 7,336.58 Canton Charter Academy (MI): $ 6,111.30 Excel Charter Academy (MI): $ 4,981.08 Walker Charter Academy (MI): $ 4,271.17 Mountain View Academy (NC): $ 3,939.42 Ridge Park Charter Academy (MI): $ 3, 793.62 Winterville Charter Academy (NC): $ 3,539.49 Knapp Charter Academy (MI): $ 3,346.37 Keystone Academy (MI): $ 2,806.91 South Pointe Scholars (MI): $2,479.13 Windemere Park Charter Academy (MI): $2,292.26 Matthews Charter Academy (NC): $2,053.08 Achieve Charter Academy (MI): $ 1,323.04 Grand River Academy (MI): $ 884.38 East Arbor Charter Academy (MI): $ 728.95 Quest Charter Academy (MI): $ 638.31 Paramount Charter Academy (MI): $626.49 Peak Charter Academy (NC): $ 502.81 Timberland Charter Academy (MI): $ 411.89 Cross Creek Charter Academy (MI): $ 246.56 Prevail Charter Academy (MI): $95.87 Total: $ 98,718.59 National Heritage Academies (NHA)® is a network of 100 tuition-free, public charter schools across nine states, serving more than 68,000 students in kindergarten through 12th grade. For more information, visit To find the nearest charter school near you, use the NHA school finder. View original content to download multimedia: SOURCE National Heritage Academies Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
FORT MYERS, Fla., June 24, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue and pipeline investment. "We are thrilled to welcome Marjorie to the NeoGenomics Board," said Lynn Tetrault, Chair of the Board of NeoGenomics. "Dr. Green's deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be invaluable as we continue to accelerate innovation into the precision oncology market." Prior to joining Merck, Dr. Green served as Senior Vice President and Head of Late-Stage Development at Seagen. Prior to that, Dr. Green was Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech. She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center. "I am honored to join NeoGenomics' Board at such an exciting time in the company's journey," said Dr. Marjorie Green. "Neo's unique oncology diagnostics offerings are well positioned for growth, and I look forward to contributing to the company's mission of improving patient care." About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on Contacts Investor Contact Kendra Sweeneyir@ Media Contact Andrea Sampsonasampson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data